Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05989711 · ClinicalTrials.gov registry record · Phase 2

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 study of Non-alcoholic Steatohepatitis (NASH), sponsored by Altimmune.

Completed
Registry status
Phase 2
Development phase
212
Enrollment target
20
Study locations

NCT05989711 is a Phase 2 study of Non-alcoholic Steatohepatitis (NASH) that has completed, run by Altimmune. The registered enrollment target is 212 participants, above the 146-participant average among 8 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05989711, a Phase 2 study of Non-alcoholic Steatohepatitis (NASH), has completed, sponsored by Altimmune.

COMPLETED
Registry status
Phase 2
Development phase
212 participants
Enrollment target
20
Study locations

Study Summary

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

Conditions Studied

Non-alcoholic Steatohepatitis (NASH)

Interventions

  • DRUG Placebo
  • DRUG Pemvidutide

Study Locations (20)

Florida

  • Altimmune Clinical Study Site - Bradenton
  • Altimmune Clinical Study Site - Fort Myers
  • Altimmune Clinical Study Site - Hialeah Gardens
  • Altimmune Clinical Study Site - Miami Lakes
  • Altimmune Clinical Study Site - Port Orange
  • Altimmune Clinical Study Site - Sarasota
  • Altimmune Clinical Study Site - West Palm Beach

Arizona

  • Altimmune Clinical Study Site - Chandler
  • Altimmune Clinical Study Site - Peoria
  • Altimmune Clinical Study Site - Tucson
  • Altimmune Clinial Study Site - Tucson

California

  • Altimmune Clinical Study Site - North Hollywood
  • Altimmune Clinical Study Site - Panorama City

Georgia

  • Altimmune Clinical Study Site - Dalton
  • Altimmune Clinical Study Site - Marietta

Louisiana

  • Altimmune Clinical Study Site - Bastrop
  • Altimmune Clinical Study Site - Shreveport

Tennessee

  • Altimmune Clinical Study Site - Clarksville
  • Altimmune Clinical Study Site - Germantown

Colorado

  • Altimmune Clinical Study Site - Englewood

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2023-07-27
Est. Completion 2025-11-25
Phase Phase 2

Sponsor

Altimmune

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05989711

The ClinicalTrials.gov registry entry for NCT05989711 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 8 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (45% higher). The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05989711 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05989711 about?

NCT05989711 is a clinical study titled "IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)". Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

What is the current status of trial NCT05989711?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2023-07-27. Estimated completion is 2025-11-25.

What conditions does trial NCT05989711 study?

This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH).

What interventions are being tested in trial NCT05989711?

The interventions under investigation include: Placebo (DRUG), Pemvidutide (DRUG).

Who is sponsoring clinical trial NCT05989711?

This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05989711 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-alcoholic Steatohepatitis (NASH)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-alcoholic Steatohepatitis (NASH)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.